Temsirolimus
Sign in to save this workspacePrimary targets: FKBP12, MTOR_FRAP1 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.740
CATDS
0.030
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Temsirolimus. Strongest target: PDK2_PDHK2 at 36.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDK2_PDHK2 | 36.6% | 63.4% |
| 2 | CAMKK2 | 32.9% | 67.1% |
| 3 | RIPK4 | 29.2% | 70.8% |
| 4 | PKMYT1 | 25.9% | 74.1% |
| 5 | WNK1 | 25.7% | 74.3% |
| 6 | STK21_CIT | 25.3% | 74.7% |
| 7 | ERN1_IRE1 | 18.0% | 82.0% |
| 8 | MUSK | 16.4% | 83.6% |
| 9 | TRPM7_CHAK1 | 16.0% | 84.0% |
| 10 | TTBK1 | 15.9% | 84.1% |
| 11 | OSR1_OXSR1 | 15.1% | 84.9% |
| 12 | EGFR | 15.0% | 85.0% |
| 13 | MLK3_MAP3K11 | 14.6% | 85.4% |
| 14 | STK33 | 14.4% | 85.6% |
| 15 | WEE1 | 14.1% | 85.9% |
| 16 | KHS_MAP4K5 | 14.0% | 86.0% |
| 17 | PKCD | 13.8% | 86.2% |
| 18 | TTBK2 | 13.6% | 86.4% |
| 19 | GSK3A | 13.5% | 86.5% |
| 20 | STK39_STLK3 | 13.4% | 86.6% |
Selectivity landscape
Where Temsirolimus sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Temsirolimus.
Atlas insights for Temsirolimus
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 247.77 | |
| ALLOGRAFT_REJECTION | 562.31 | |
| ANDROGEN_RESPONSE | 322.65 | |
| ANGIOGENESIS | 104.02 | |
| APICAL_JUNCTION | 730.10 | |
| APICAL_SURFACE | 63.43 | |
| APOPTOSIS | 804.26 | |
| BILE_ACID_METABOLISM | 113.02 | |
| CHOLESTEROL_HOMEOSTASIS | 189.76 | |
| COAGULATION | 70.39 | |
| COMPLEMENT | 465.00 | |
| DNA_REPAIR | 255.23 | |
| E2F_TARGETS | 668.66 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 230.96 | |
| ESTROGEN_RESPONSE_EARLY | 389.05 | |
| ESTROGEN_RESPONSE_LATE | 317.92 | |
| FATTY_ACID_METABOLISM | 86.49 | |
| G2M_CHECKPOINT | 564.16 | |
| GLYCOLYSIS | 313.70 | |
| HEDGEHOG_SIGNALING | 133.54 | |
| HEME_METABOLISM | 137.19 | |
| HYPOXIA | 457.38 | |
| IL2_STAT5_SIGNALING | 319.70 | |
| IL6_JAK_STAT3_SIGNALING | 410.10 | |
| INFLAMMATORY_RESPONSE | 414.82 | |
| INTERFERON_ALPHA_RESPONSE | 77.93 | |
| INTERFERON_GAMMA_RESPONSE | 502.18 | |
| KRAS_SIGNALING_DN | 126.38 | |
| KRAS_SIGNALING_UP | 286.26 | |
| MITOTIC_SPINDLE | 670.02 | |
| MTORC1_SIGNALING | 344.57 | |
| MYC_TARGETS_V1 | 421.43 | |
| MYC_TARGETS_V2 | 100.89 | |
| MYOGENESIS | 352.24 | |
| NOTCH_SIGNALING | 86.34 | |
| OXIDATIVE_PHOSPHORYLATION | 106.51 | |
| P53_PATHWAY | 393.48 | |
| PANCREAS_BETA_CELLS | 53.72 | |
| PEROXISOME | 97.53 | |
| PI3K_AKT_MTOR_SIGNALING | 841.65 | |
| PROTEIN_SECRETION | 201.87 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 72.97 | |
| SPERMATOGENESIS | 203.85 | |
| TGF_BETA_SIGNALING | 268.59 | |
| TNFA_SIGNALING_VIA_NFKB | 560.85 | |
| UNFOLDED_PROTEIN_RESPONSE | 170.83 | |
| UV_RESPONSE_DN | 389.81 | |
| UV_RESPONSE_UP | 405.88 | |
| WNT_BETA_CATENIN_SIGNALING | 368.94 | |
| XENOBIOTIC_METABOLISM | 162.42 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.881 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.857 |
| SRR23303752 | — | 0.846 |
| aMVAC.P_005_TURBT_S223 | — | 0.844 |
| SRR12202498 | — | 0.842 |
Annotations
Sign in to read and post annotations.
Loading…